Pharmacovigilance - The next chapter

被引:122
作者
Moore, Nicholas [1 ]
Berdai, Driss [2 ]
Blin, Patrick [1 ]
Droz, Cecile [1 ]
机构
[1] Univ Bordeaux, Inserm CIC1401, Bordeaux PharmacoEpi, F-33076 Bordeaux, France
[2] CHU Bordeaux, F-33076 Bordeaux, France
来源
THERAPIE | 2019年 / 74卷 / 06期
关键词
Drug safety; Pharmacovigilance; Pharmacoepidemiology; Population databases; ADVERSE DRUG-REACTIONS; SPONTANEOUS REPORTING DATABASES; INDUCED LIVER DISORDERS; CAUSALITY ASSESSMENT; COMPETITION BIAS; DISPROPORTIONALITY MEASURES; CONSENSUS MEETINGS; SIGNAL GENERATION; EXPERT JUDGMENT; FRENCH METHOD;
D O I
10.1016/j.therap.2019.09.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The discovery and quantification of adverse drug reactions has tong relied on the careful analysis of spontaneously reported cases. Causality assessment (imputation) was a fundamental feature of individual case report analysis. This was complemented by analysis of aggregated cases, and of disproportionatity analyses in spontaneous reports databases. In the absence of more specific information sources, these have resulted in the discovery of many new adverse reactions, altering drug information. It has led to the withdrawal from the market of many drugs, but its use for risk quantification remains fraught with uncertainty. The recent access to population-wide claims or electronic health records databases have confirmed for spontaneous reporting a predominant role in hypothesis generation for serious adverse drug reactions, notably those that result in hospital admission or death. In these cases, the events are identifiable at the population level, and can be quantified precisely using the toots of modern pharmacoepidemiology, to generate specific benefit-risk analyses. Spontaneous reporting remains irreplaceable in signal and alert generation in drug safety, despite its inherent limitations. For signal strengthening and assessment, more systematic and quantitative methods should be sought, such as claims databases for reactions resulting in hospital admissions. (C) 2019 Published by Elsevier Masson SAS on behalf of Societe francaise de pharmacologie et de therapeutique.
引用
收藏
页码:557 / 567
页数:11
相关论文
共 97 条
[61]  
2-F
[62]   Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2 million young girls in France [J].
Miranda, Sara ;
Chaignot, Christophe ;
Collin, Cedric ;
Dray-Spira, Rosemary ;
Weill, Alain ;
Zureik, Mahmoud .
VACCINE, 2017, 35 (36) :4761-4768
[63]  
MIREMONT G, 1994, EUR J CLIN PHARMACOL, V46, P285
[64]   Causality assessment in pharmacovigilance: The French method and its successive updates [J].
Miremont-Salame, Ghada ;
Theophile, Helelne ;
Haramburu, Francoise ;
Begaud, Bernard .
THERAPIE, 2016, 71 (02) :179-186
[65]  
MOORE N, 1985, LANCET, V2, P1056
[66]   The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions [J].
Moore, N ;
Thiessard, F ;
Begaud, B .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2005, 14 (04) :285-286
[67]   Assessing drug safety [J].
Moore, N .
BRITISH MEDICAL JOURNAL, 2005, 330 (7490) :539-540
[68]   Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole [J].
Moore, N ;
Hall, G ;
Sturkenboom, M ;
Mann, R ;
Lagnaoui, R ;
Begaud, B .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2003, 12 (04) :271-281
[69]  
Moore N, 1994, PHARMACOEPIDERMIOL D, V3, P157
[70]  
Moore N, 1994, PHARMACOEPIDEM DR S, V3, P151